Page 131 - 2019_04-Haematologica-web

Thromboembolism and thromboprophylaxis in pediatric ALL
Figure 1. Consolidated standards for reporting of trials (CONSORT) diagram. AT: antithrombin; E: enoxaparin; UFH: unfractionated heparin.
Table 1. Patients’ characteristics by thromboprophylaxis group as assigned by randomization.
Study
ALL-BFM 2000 AIEOP-BFM ALL 2009
Sex Male Female
Age
1≤6 years 6≤10 years ≥ 10 years
Central venous catheter CVC in site
No CVC
815 (85.9) 134 (14.1)
537 (56.6)
412 (43.4)
512 (54.0) 188 (19.8) 249 (26.2)
896 (94.4)
53 (5.6)
599 (63.1) 249 (26.2) 53 (5.6) 47 (5.0)
872 (91.9) 30 (3.2) 47 (5.0)
827 (87.1) 120 (12.6) 2 (0.2)
269 (86.2) 43 (13.8)
173 (55.4)
139 (44.6)
174 (55.8) 57 (18.3) 81 (26.0)
295 (94.6)
17 (5.4)
199 (63.8) 83 (26.6) 15 (4.8) 15 (4.8)
278 (89.1) 14 (4.4) 20 (6.4)
264 (84.6) 47 (15.1) 1 (0.3)
272 (85.8) 45 (14.2)
183 (57.7)
133 (42.3)
157 (49.5) 72 (22.9) 88 (27.8)
294 (93.3)
21 (6.7)
212 (66.9) 76 (24.0) 14 (4.4) 14 (4.4)
298 (94.0) 6 (1.9) 13 (4.1)
298 (89.0) 34 (10.7) 1 (0.3)
274 (85.6) 44 (13.8)
181 (56.6)
139 (43.4)
181 (56.6) 59 (18.4) 80 (25.0)
303 (95.2)
15 (4.8)
188 (58.8) 90 (28.1) 24 (7.4) 18 (5.6)
296 (92.5) 10 (3.1) 14 (4.4)
281 (87.8) 39 (12.3) 0 (0.0)
Total (n=949) UFH (n=312) Enoxaparin (n=317) Antithrombin (n=320) N(%) N(%) N(%) N(%)
WBC at diagnosis (x109/L) <20
20≤100 100 ≤200 ≥ 200
CNS status
CNS negative CNS positive No information
Immunophenotype Non-T-ALL
T-ALL
No information
continued on the next page
haematologica | 2019; 104(4)
759